Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preoperative Co-Mutation of BRAFV600E and TERT Promoter Predicts Tumor Aggressiveness and Recurrence-Free Survival in Papillary Thyroid Carcinoma.

Cancer medicine - 1 Jun 2026

Deng Chang, Cao Yijia, Deng Yuping, Chun Lin, Xinliang Su

Abstract excerpt

BACKGROUND: The individual prognostic impacts of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma (PTC) are established, but the clinical significance of their co-occurrence, especially when assessed preoperatively, requires further elucidation. OBJECTIVE: To evaluate the clinicopathological features and recurrence risk associated with the combined BRAFV600E/TERT mutation in PTC using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Neoplasm Recurrence, Local

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Promoter Regions, Genetic

Share to Proto-Oncogene Proteins B-raf

Share to Telomerase

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42260747
DOI: 10.1002/cam4.72029
PMCID: PMC13247126

Genes

TERT
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preoperative Co-Mutation of BRAFV600E and TERT Promoter Predicts Tumor Aggressiveness and Recurrence-Free Survival in Papillary Thyroid Carcinoma.PMID 42260747Read ↗

Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis.Semantic proximity Read ↗

Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid CancerSemantic proximity Read ↗

Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis.Semantic proximity Read ↗

The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis.Semantic proximity Read ↗

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.Semantic proximity Read ↗

Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasisSemantic proximity Read ↗

Association Between Gross Features and Coexistence of BRAFV600E and TERT Promoter Mutations in Papillary Thyroid Carcinomas: A Combined Analysis Incorporating Clinicopathologic Features.Semantic proximity Read ↗

BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.Semantic proximity Read ↗

Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer.Semantic proximity Read ↗

Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer.Semantic proximity Read ↗

A six-genotype genetic prognostic model for papillary thyroid cancer.Semantic proximity Read ↗

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in KoreaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.